Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeWVEWave Life Sciences$10.81+3.9%$11.31$4.25▼$16.74$1.66B-1.041.11 million shs1.49 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceWVEWave Life Sciences+10.76%-7.39%-6.89%-32.51%+52.94%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationWVEWave Life Sciences4.421 of 5 stars3.52.00.04.82.44.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceWVEWave Life Sciences 3.00Buy$22.60109.07% UpsideCurrent Analyst Ratings BreakdownLatest WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2025WVEWave Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.002/25/2025WVEWave Life SciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.00(Data available from 3/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookWVEWave Life Sciences$108.30M15.32N/AN/A$0.40 per share27.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateWVEWave Life Sciences-$57.51M-$0.79N/AN/AN/A-66.50%-280.57%-52.90%5/8/2025 (Estimated)Latest WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/2025Q4 2024WVEWave Life Sciences-$0.17$0.17+$0.34$0.17$25.60 million$83.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthWVEWave Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioWVEWave Life SciencesN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipWVEWave Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipWVEWave Life Sciences29.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableWVEWave Life Sciences240153.49 million108.14 millionOptionableWVE HeadlinesRecent News About These CompaniesWave Life Sciences (NASDAQ:WVE) Shares Up 13.1% - Still a Buy?March 12 at 5:55 PM | marketbeat.comContrasting Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM)March 10 at 1:05 AM | americanbankingnews.comResearch Analysts Set Expectations for WVE FY2025 EarningsMarch 9 at 2:09 AM | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno Sells 169,025 SharesMarch 8, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Stock Price Down 6.1% - Here's What HappenedMarch 8, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for WVE FY2025 Earnings?March 8, 2025 | marketbeat.comPaul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) StockMarch 8, 2025 | insidertrades.comB. Riley Reduces Earnings Estimates for Wave Life SciencesMarch 8, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Upgraded by StockNews.com to Hold RatingMarch 8, 2025 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Rating Increased to Hold at StockNews.comMarch 8, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for WVE Q1 Earnings?March 8, 2025 | americanbankingnews.comQ1 EPS Estimates for Wave Life Sciences Lowered by B. RileyMarch 8, 2025 | americanbankingnews.comQ1 Earnings Estimate for WVE Issued By HC WainwrightMarch 7, 2025 | marketbeat.comWave Life Sciences (NASDAQ:WVE) Stock Price Down 6.1% - Should You Sell?March 6, 2025 | marketbeat.comWave Life Sciences Ltd. (WVE) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comHC Wainwright Reiterates "Buy" Rating for Wave Life Sciences (NASDAQ:WVE)March 6, 2025 | marketbeat.comAnalysts Set Wave Life Sciences Ltd. (NASDAQ:WVE) Price Target at $22.60March 6, 2025 | americanbankingnews.comB.Riley Financial Sticks to Its Buy Rating for Wave Life Sciences (WVE)March 5, 2025 | markets.businessinsider.comWave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comWave Life Sciences (NASDAQ:WVE) Trading Up 5.4% on Strong EarningsMarch 5, 2025 | marketbeat.com24,461 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Acquired by Los Angeles Capital Management LLCMarch 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWVE Company DescriptionsWave Life Sciences NASDAQ:WVE$10.81 +0.41 (+3.94%) Closing price 04:00 PM EasternExtended Trading$10.80 -0.01 (-0.13%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
